logo
logo

Heartseed Raises $37 Million In Series C Funding To Accelerate Development Of Ipsc-Derived Stem Cell Therapy For Heart Failure

Heartseed Raises $37 Million In Series C Funding To Accelerate Development Of Ipsc-Derived Stem Cell Therapy For Heart Failure

06/11/21, 7:07 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/JP.svgtokyo
Money raised
$37 million
Round Type
series c
Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.

Company Info

Company
Heartseed
Location
tokyo, tokyo, japan
Additional Info
Heartseed will use the new funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.